EUVIMEDEUVIMED entdecken
Crossref

Discovery of 5‐(1‐benzyl‐1H‐imidazol‐4‐yl)‐1,2,4‐oxadiazole derivatives as novel RIPK1 inhibitors via structure‐based virtual screening

Yanzhen Yu, Yunzhen Hu, Huihui Yan, Xin Zeng, Haodong Yang, Lei Xu, Rong Sheng iD

Drug Development Research · 2024

DOI: 10.1002/ddr.22235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2024. Verfasst von Yanzhen Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, Oxadiazoles, Protein Kinase Inhibitors, Molecular Dynamics Simulation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RIPK1 plays a key role in necroptosis and is associated with various inflammatory diseases. Using structure‐based virtual screening, a novel hit with 5‐(1‐benzyl‐1H‐imidazol‐4‐yl)‐1,2,4‐oxadiazole scaffold was identified as an RIPK1 inhibitor with an IC 50 value of 1.3 μM. Further structure–activity relationship study was performed based on similarity research and biological evaluation. The molecular dynamics simulation of compound 2 with RIPK1 indicated that it may act as a type II kinase inhibitor. This study provides a highly efficient way to discover novel scaffold RIPK1 inhibitors for further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor-Interacting Protein Serine-Threonine KinasesOxadiazolesProtein Kinase InhibitorsMolecular Dynamics SimulationHumansStructure-Activity RelationshipMolecular Docking SimulationImidazolesDrug Evaluation, PreclinicalDrug Discovery

Stichwörter der Autor:innen

RIPK1 inhibitorsmolecular dynamicsvirtual screening

Substanzen

Receptor-Interacting Protein Serine-Threonine KinasesOxadiazolesRIPK1 protein, humanProtein Kinase InhibitorsImidazoles

Autor:innen und Institutionen

  • College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Jinhua Institute of Zhejiang University, Zhejiang University, Jinhua, China.
  • Institute of Bioinformatics and Medical Engineering, School of Electrical and Information Engineering, Jiangsu University of Technology, Changzhou, China.

ORCID-Profile: Rong Sheng

Zitieren

APA

Yu, Y., Hu, Y., Yan, H., Zeng, X., Yang, H., Xu, L., & Sheng, R. (2024). Discovery of 5‐(1‐benzyl‐1H‐imidazol‐4‐yl)‐1,2,4‐oxadiazole derivatives as novel RIPK1 inhibitors via structure‐based virtual screening. Drug Development Research. https://doi.org/10.1002/ddr.22235

Vancouver

Yu Y, Hu Y, Yan H, Zeng X, Yang H, Xu L, et al. Discovery of 5‐(1‐benzyl‐1H‐imidazol‐4‐yl)‐1,2,4‐oxadiazole derivatives as novel RIPK1 inhibitors via structure‐based virtual screening. Drug Development Research. 2024. doi:10.1002/ddr.22235

BibTeX
@article{Yu2024,
  author = {Yu, Yanzhen and Hu, Yunzhen and Yan, Huihui and Zeng, Xin and Yang, Haodong and Xu, Lei and Sheng, Rong},
  title = {Discovery of 5‐(1‐benzyl‐1H‐imidazol‐4‐yl)‐1,2,4‐oxadiazole derivatives as novel RIPK1 inhibitors via structure‐based virtual screening},
  journal = {Drug Development Research},
  year = {2024},
  doi = {10.1002/ddr.22235}
}
Kostenlos starten →